Hemostasis Products Market Size - By Product (Topical Hemostasis Product, Infusible Hemostasis Products, Advanced Hemostasis Products), By Application (Trauma, Surgery, Hemophilia, Myocardial Infarction), By End-use & – Global Forecast to 2032

Hemostasis Products Market Size - By Product (Topical Hemostasis Product, Infusible Hemostasis Products, Advanced Hemostasis Products), By Application (Trauma, Surgery, Hemophilia, Myocardial Infarction), By End-use & – Global Forecast to 2032

Hemostasis Products Market Size

Hemostasis Products Market size was worth USD 1.6 billion in 2022 and is poised to record substantial growth at 5.8% CAGR from 2023-2032, driven by the escalating prevalence of cardiac disorders across the globe.
 

The growing popularity of hemostasis products to ensure patient safety and positive outcomes during surgeries, interventions, and other medical procedures related to heart conditions will drive the industry gains.  The increasing prevalence of cardiovascular diseases has spurred the rising demand for effective solutions to manage bleeding during cardiac procedures. Moreover, the aging population and unhealthy lifestyle trends are contributing to the expanding cardiac patient pool, driving the demand for hemostasis products. According to the American Heart Association statistics, cardiovascular disease globally accounts for more than 17.6 million deaths per year and is estimated to reach over 23.6 million by 2030. The rising number of R&D investments to enhance product efficacy, safety, and ease of use.
 

The growing technological advancements and the rising application areas of hemostat products will contribute to the industry expansion. However, the development and incorporation of cutting-edge technologies are increasing production costs, subsequently impacting the pricing of hemostasis solutions. Nevertheless, the focus of manufacturers and stakeholders towards balancing technological advancements and affordability to ensure wider market penetration and sustained progression.
 

Impact of COVID-19 Pandemic

The COVID-19 pandemic had negative impact on the demand for hemostasis products due to the detrimental effects on the operations of multiple internationally functioning industries. The major disruptions in their respective supply-chain operations and production was mainly driven by precautionary lockdowns and the rigorous rules imposed by governing bodies globally.  Furthermore, the growing emphasis of consumers on cutting down superfluous spending from their budgets.
 

Hemostasis Products Market Trends

Recent innovations, such as modified chitosan dressing, intranasal splint for nasal/sinus surgery and hemostatic foams have proved favorable for considerable industry gains. The demand for microfibrillar collagen hemostats has picked significant pace to demonstrate quick hemostasis and favorable outcomes in favor of the patient, as well as in some other documented issues. The growing emphasis on providing technologically superior hemostasis solutions will also drive the business expansion. For instance, in May 2023, Sysmex Corporation inked a global OEM agreement on hemostasis products with Siemens Healthcare Diagnostics Inc., for the supply of its OEM hemostasis diagnostic devices.
 

Hemostasis Products Market Analysis

Topical hemostasis products market is estimated to reach over USD 2 billion by 2032 due to advantages, such as ease of application, quick action, and reduced risk of complications. Moreover, the rising number of accidents worldwide coupled with the increasing incidence of surgeries along with the surging need of minimizing blood loss, reducing transfusions, and accelerating patient recovery. According to the National Highway Traffic Safety Administration, 31,785 persons died in traffic accidents in the first nine months of 2022.
 

Hemostasis products market size from the surgery segment is expected to exceed USD 988 million by 2032 due to the increasing number of more advanced and intricate surgeries to treat multiple diseases. The rising prevalence of cardiovascular and orthopedic surgeries as well as general procedures has resulted in the sustained demand for hemostasis products. According to the Lancet Commission, the global burden of surgically treatable diseases is estimated to rise by 60% in 2030. 
 

North America hemostasis products market size is expected to record 5.9% CAGR from 2023-2032. The presence of large geriatric population base coupled with lifestyle-related factors, such as obesity and sedentary habits are contributing to the increasing incidence of cardiovascular diseases. For instance, in July 2023, Baxter International Inc., a worldwide leader in surgical innovation, launched PERCLOT Absorbable Hemostatic Powder, a ready-to-use product developed for patients with intact coagulation to treat minor bleeding in the U.S.,
 

Hemostasis Products Market Share

The competitive landscape of the hemostasis products market includes prominent firms, such as

• Johnson & Johnson
• Pfizer
• Baxter International
• Medtronic
• B. Braun Melsungen AG
• Becton
• Dickinson and Company (BD)
• Tricol Biomedical
• Hemostasis LLC
• CuraMedical BV
• Teleflex Incorporated
   

Hemostasis Products Industry News

• In September 2022, Medtronic announced that its Nexpowder endoscopic hemostasis device was cleared by the FDA. Through this initiative, the firm aims to develop transformative technologies to enhance outcomes and improve standard of care.
   

Hemostasis products market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

By Product (USD Million)

• Topical hemostasis products
  • Gelatin
  • Polysaccharides
  • Oxidized regenerated cellulose
  • Collagen
• Infusible hemostasis products
  • Fresh frozen plasma (FFP)
  • Factor VIII
  • Platelet concentrate from donor blood
  • Prothrombin
• Advanced hemostasis products
  • Flowable
  • Thrombin
  • Synthetic sealant
  • Fibrin

By Application (USD Million)

• Trauma
• Surgery
• Hemophilia
• Myocardial infarction
• Others

By End-use (USD Million)

• Hospitals
• Ambulatory surgery centers
• Others

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Switzerland
  • The Netherlands
  • Denmark
  • Poland
  • Sweden
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • New Zealand
  • Thailand
  • Vietnam
  • Indonesia
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Turkey